Studies have revealed that BRAF (B-Raf proto-oncogene, serine/threonine kinase), KRAS (Kirsten rat sarcoma), NRAS (neuroblastoma RAS viral oncogene homolog), HRAS (Harvey Rat sarcoma viral oncogene), CDKN2B (Cyclin dependent kinase inhibitor 2B), PTEN (phosphatase and the tensin homolog deleted on chromosome 10), TERT (telomerase reverse transcriptase), and p53 are the most commonly mutated genes in MM progression, which can potentially cause resistance to targeted therapy. Here, NRAS is linked to Miyoshi myopathy.